company background image
4591 logo

Ribomic TSE:4591 Stock Report

Last Price

JP¥91.00

Market Cap

JP¥3.2b

7D

-1.1%

1Y

-50.3%

Updated

27 Mar, 2024

Data

Company Financials

4591 Stock Overview

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan.

4591 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Ribomic Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ribomic
Historical stock prices
Current Share PriceJP¥91.00
52 Week HighJP¥199.00
52 Week LowJP¥88.00
Beta0.55
1 Month Change-7.14%
3 Month Change-13.33%
1 Year Change-50.27%
3 Year Change-75.00%
5 Year Change-85.58%
Change since IPO-95.22%

Recent News & Updates

Recent updates

Shareholder Returns

4591JP BiotechsJP Market
7D-1.1%-2.0%1.0%
1Y-50.3%-23.2%38.6%

Return vs Industry: 4591 underperformed the JP Biotechs industry which returned -23.2% over the past year.

Return vs Market: 4591 underperformed the JP Market which returned 38.6% over the past year.

Price Volatility

Is 4591's price volatile compared to industry and market?
4591 volatility
4591 Average Weekly Movement6.5%
Biotechs Industry Average Movement7.8%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.3%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4591's share price has been volatile over the past 3 months.

Volatility Over Time: 4591's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
200325Yoshikazu Nakamurahttps://www.ribomic.com

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

Ribomic Inc. Fundamentals Summary

How do Ribomic's earnings and revenue compare to its market cap?
4591 fundamental statistics
Market capJP¥3.25b
Earnings (TTM)-JP¥979.00m
Revenue (TTM)JP¥62.00m

52.4x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4591 income statement (TTM)
RevenueJP¥62.00m
Cost of RevenueJP¥0
Gross ProfitJP¥62.00m
Other ExpensesJP¥1.04b
Earnings-JP¥979.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 14, 2024

Earnings per share (EPS)-27.44
Gross Margin100.00%
Net Profit Margin-1,579.03%
Debt/Equity Ratio0%

How did 4591 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.